Genelux Q3 net loss widens on higher R&D costs
GNLX•Genelux reported a third-quarter net loss of $10.29 million, missing the $8.78 million analyst consensus, as higher clinical and regulatory costs lifted expenses. The company expects cash and investments to fund operations into the first quarter of 2027.
1. Quarterly results
Genelux's third-quarter net loss widened and missed analyst expectations. Operating expenses were $10.40 million, with higher clinical and regulatory costs for its Phase 3 OnPrime/GOG-3076 trial driving increased research and development spending.
2. Pipeline and cash outlook
Genelux expects topline data from the Phase 3 OnPrime ovarian cancer trial in the second half of 2026 and additional lung cancer dose-escalation updates by year-end 2026. It expects cash and investments to fund operations into the first quarter of 2027.




